Recently, a group from Leuven (Belgium) conducted a small clinical trial with a CB2 tracer, [11C]NE40 [18] and reported no differences in the [11C]NE40 binding potential between AD patients and age-matched controls. This evidence concerns the gene CNR2 and Alzheimer disease.